von Willebrand factor antigen (vWF-Ag): A non-invasive predictor of treatment response and serious adverse events in HCV patients with interferon triple therapy
Standard
von Willebrand factor antigen (vWF-Ag): A non-invasive predictor of treatment response and serious adverse events in HCV patients with interferon triple therapy. / Horvatits (Rutter), Karoline; Etschmaier, Alexandra; Ferlitsch, Monika; Maieron, Andreas; Hametner, Stephanie; Horvatits, Thomas; Paternostro, Rafael; Salzl, Petra; Reiberger, Thomas; Peck-Radosavljevic, Markus; Quehenberger, Peter; Hofer, Harald; Trauner, Michael; Ferenci, Peter; Ferlitsch, Arnulf.
In: DIGEST LIVER DIS, Vol. 48, No. 10, 10.2016, p. 1194-9.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - von Willebrand factor antigen (vWF-Ag): A non-invasive predictor of treatment response and serious adverse events in HCV patients with interferon triple therapy
AU - Horvatits (Rutter), Karoline
AU - Etschmaier, Alexandra
AU - Ferlitsch, Monika
AU - Maieron, Andreas
AU - Hametner, Stephanie
AU - Horvatits, Thomas
AU - Paternostro, Rafael
AU - Salzl, Petra
AU - Reiberger, Thomas
AU - Peck-Radosavljevic, Markus
AU - Quehenberger, Peter
AU - Hofer, Harald
AU - Trauner, Michael
AU - Ferenci, Peter
AU - Ferlitsch, Arnulf
N1 - Copyright © 2016 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
PY - 2016/10
Y1 - 2016/10
N2 - BACKGROUND: Treatment of chronic hepatitis C virus (HCV) infection was revolutionized within the last years. Interferon free antiviral regimens are not accessible without limitations. Combination of peginterferon/ribavirin with first generation direct acting antivirals is less effective and associated with serious adverse events.AIM: We have shown that vWF-Ag is associated with portal hypertension and treatment response to PEG/RBV and we evaluated if vWF-Ag is a predictive marker for treatment response and safety in patients with triple therapy.METHODS: 222 HCV-GT 1 patients and DAA based triple therapy were included in this retrospective, multicenter study.RESULTS: Median vWF-Ag levels were 167.0% [IQR: 124.0-210.0%]. Significantly higher levels were seen in patients without SVR; median 190% [IQR: 146.0-259.5%] versus SVR: 142.5% [IQR: 114.3-196.8%], p<0.001. Furthermore levels of vWF-Ag were identified as independent predictor of non SVR; (OR: 1.009; 95%CI: 1.016-1.3, p=0.005). In patients with cirrhosis elevated vWF-Ag levels were associated with increased incidence of SAEs (OR: 1.016; 95%CI: 1.004-1.028; p=0.007). Best cut off for prediction of SAEs was vWF-Ag>281.5% with a sensitivity of 78% and a specificity of 90%.CONCLUSION: Baseline vWF-Ag levels predict outcome of DAA based treatment in HCV-1 patients and identify patients with a risk of SAEs. Therefore vWF-Ag may be an additional marker for selecting patients for interferon free therapeutic regimens.
AB - BACKGROUND: Treatment of chronic hepatitis C virus (HCV) infection was revolutionized within the last years. Interferon free antiviral regimens are not accessible without limitations. Combination of peginterferon/ribavirin with first generation direct acting antivirals is less effective and associated with serious adverse events.AIM: We have shown that vWF-Ag is associated with portal hypertension and treatment response to PEG/RBV and we evaluated if vWF-Ag is a predictive marker for treatment response and safety in patients with triple therapy.METHODS: 222 HCV-GT 1 patients and DAA based triple therapy were included in this retrospective, multicenter study.RESULTS: Median vWF-Ag levels were 167.0% [IQR: 124.0-210.0%]. Significantly higher levels were seen in patients without SVR; median 190% [IQR: 146.0-259.5%] versus SVR: 142.5% [IQR: 114.3-196.8%], p<0.001. Furthermore levels of vWF-Ag were identified as independent predictor of non SVR; (OR: 1.009; 95%CI: 1.016-1.3, p=0.005). In patients with cirrhosis elevated vWF-Ag levels were associated with increased incidence of SAEs (OR: 1.016; 95%CI: 1.004-1.028; p=0.007). Best cut off for prediction of SAEs was vWF-Ag>281.5% with a sensitivity of 78% and a specificity of 90%.CONCLUSION: Baseline vWF-Ag levels predict outcome of DAA based treatment in HCV-1 patients and identify patients with a risk of SAEs. Therefore vWF-Ag may be an additional marker for selecting patients for interferon free therapeutic regimens.
KW - Journal Article
U2 - 10.1016/j.dld.2016.06.033
DO - 10.1016/j.dld.2016.06.033
M3 - SCORING: Journal article
C2 - 27476467
VL - 48
SP - 1194
EP - 1199
JO - DIGEST LIVER DIS
JF - DIGEST LIVER DIS
SN - 1590-8658
IS - 10
ER -